Eli Lilly (LLY) Financial Analysis & Valuation | Quarter Chart
Eli Lilly (LLY)
LLYPrice: $1083.73
Fair Value: 🔒
🔒score
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, a... more
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Ba... more
Description
Shares
| Market Cap | $1.02T | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | David A. Ricks |
| IPO Date | 1972-06-01 | CAGR | 0.08% |
| Employees | 47,000 | Website | www.lilly.com |
| Div. Yield | 0.6% | Payout Ratio | 0.22% |
| Buy Back Yield | 0.51% | Total Yield | 1.11% |
LLY chart loading...
Fundamentals
Technicals
| Enterprise Value | $878.46B | P/E Ratio | 38.55 |
| Forward P/E | 24.85 | PEG Ratio | 0.23 |
| P/S Ratio | 14.15 | P/B Ratio | 31.15 |
| P/CF Ratio | 47.43 | P/FCF Ratio | 75.32 |
| EPS | $28.11 | EPS Growth 1Y | 129.05% |
| EPS Growth 3Y | 359.97% | EPS Growth 5Y | 342.61% |
| Revenue Growth 1Y | 47.44% | Gross Margin | 0.84% |
| Operating Margin | 0.46% | Profit Margin | 0.35% |
| ROE | 1.01% | ROA | 0.22% |
| ROCE | 0.41% | Current Ratio | 1.5 |
| Quick Ratio | 1.1 | Cash Ratio | 0.14 |
| Debt/Equity | 1.39 | Interest Coverage | 37.5 |
| Altman Z Score | 9.23 | Piotroski Score | 6 |